Key result
In elderly Japanese patients with nonvalvular atrial fibrillation, a time in therapeutic range (TTR) of ≥55.6% during warfarin therapy was independently associated with a reduced risk of ischemic events (HR 0.54, 95% CI 0.30-0.96, p=0.037).
Why the study?
Does higher Time in Therapeutic Range (TTR) reduce ischemic and hemorrhagic events in elderly Japanese patients with nonvalvular atrial fibrillation on warfarin?
Cohort (n=512)
Yes
Does higher Time in Therapeutic Range (TTR) reduce ischemic and hemorrhagic events in elderly Japanese patients with nonvalvular atrial fibrillation on warfarin?
Hazard Ratio: 0.54 (95% CI 0.3–0.96)
p-value: p=0.037
In elderly Japanese patients with nonvalvular atrial fibrillation, maintaining a warfarin TTR ≥55.6% for a target PT-INR of 1.6-2.6 significantly reduces ischemic events without a clear impact on major bleeding.
TTR ≥55.6% was associated with lower ischemic risk in elderly Japanese NVAF on warfarin; leaves open optimal targets for prospective trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Nakajima et al. (2016) conducted a cohort in Nonvalvular atrial fibrillation (n=512). Time in therapeutic range (TTR) ≥55.6% vs. TTR <55.6% was evaluated on Ischemic events (HR 0.54, 95% CI 0.30-0.96, p=0.037). In elderly Japanese patients with nonvalvular atrial fibrillation, a time in therapeutic range (TTR) of ≥55.6% during warfarin therapy was independently associated with a reduced risk of ischemic events (HR 0.54, 95% CI 0.30-0.96, p=0.037).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: